ALAD porphyria is a conformational disease.

Am J Hum Genet

Fox Chase Cancer Center, Philadelphia, PA 19111, USA.

Published: February 2007

ALAD porphyria is a rare porphyric disorder, with five documented compound heterozygous patients, and it is caused by a profound lack of porphobilinogen synthase (PBGS) activity. PBGS, also called "delta-aminolevulinate dehydratase," is encoded by the ALAD gene and catalyzes the second step in the biosynthesis of heme. ALAD porphyria is a recessive disorder; there are two common variant ALAD alleles, which encode K59 and N59, and eight known porphyria-associated ALAD mutations, which encode F12L, E89K, C132R, G133R, V153M, R240W, A274T, and V275M. Human PBGS exists as an equilibrium of functionally distinct quaternary structure assemblies, known as "morpheeins," in which one functional homo-oligomer can dissociate, change conformation, and reassociate into a different oligomer. In the case of human PBGS, the two assemblies are a high-activity octamer and a low-activity hexamer. The current study quantifies the morpheein forms of human PBGS for the common and porphyria-associated variants. Heterologous expression in Escherichia coli, followed by separation of the octameric and hexameric assemblies on an ion-exchange column, showed that the percentage of hexamer for F12L (100%), R240W (80%), G133R (48%), C132R (36%), E89K (31%), and A274T (14%) was appreciably larger than for the wild-type proteins K59 and N59 (0% and 3%, respectively). All eight porphyria-associated variants, including V153M and V275M, showed an increased propensity to form the hexamer, according to a kinetic analysis. Thus, all porphyria-associated human PBGS variants are found to shift the morpheein equilibrium for PBGS toward the less active hexamer. We propose that the disequilibrium of morpheein assemblies broadens the definition of conformational diseases beyond the prion disorders and that ALAD porphyria is the first example of a morpheein-based conformational disease.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1785348PMC
http://dx.doi.org/10.1086/511444DOI Listing

Publication Analysis

Top Keywords

alad porphyria
16
human pbgs
16
conformational disease
8
k59 n59
8
n59 porphyria-associated
8
porphyria-associated variants
8
alad
7
pbgs
7
porphyria conformational
4
disease alad
4

Similar Publications

Profound hypotonia in an infant with δ-aminolevulinic acid dehydratase deficient porphyria.

Eur J Hum Genet

December 2024

Department of Neonatology, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, AR, USA.

δ-Aminolevulinic acid (ALA) dehydratase (ALAD) deficient porphyria (ADP) is an extremely rare form of porphyria, with only eight documented cases. Herein, we report the second known case of ADP in the Western hemisphere and third case with infantile onset of symptoms. A male neonate presented on day three of life with profound hypotonia, pinpoint pupils, absent deep tendon reflexes, and anemia.

View Article and Find Full Text PDF
Article Synopsis
  • The acute hepatic porphyrias (AHP) are rare genetic disorders that disrupt heme metabolism, with acute intermittent porphyria being the most common and presenting mainly in women aged 15-50 with severe abdominal pain.
  • Key diagnostic tests include measuring urine porphobilinogen and δ-aminolevulinic acid, and patients with elevated levels are presumed to have AHP until proven otherwise.
  • Management includes stopping triggering medications, providing supportive treatments (like dextrose and hemin), and considering liver transplantation for those with severe and unmanageable symptoms.
View Article and Find Full Text PDF

Acute intermittent porphyria (AIP) is a rare disease caused by a deficiency of hydroxymethylbilane synthase (HMBS), the third enzyme of the heme-synthesis pathway. Decreased enzymatic activity in the liver induces an overproduction of heme-precursors and acute neurological attacks. We report a 36-years-old female with AIP with a long-term history of severe, disabling, recurrent attacks, who underwent curative liver transplantation.

View Article and Find Full Text PDF

ALAD Inhibition by Porphobilinogen Rationalizes the Accumulation of δ-Aminolevulinate in Acute Porphyrias.

Biochemistry

November 2022

Precision Medicine and Metabolism Laboratory, CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Bizkaia Science and Technology Park, 48160 Derio, Spain.

Article Synopsis
  • Patients with acute hepatic porphyrias experience neurological attacks due to an overproduction of porphobilinogen (PBG) and δ-aminolevulinic acid (ALA).
  • In acute intermittent porphyria (AIP), gene mutations cause a deficiency in the enzyme PBG deaminase, leading to PBG buildup, although the exact accumulation of ALA remains unclear.
  • Research findings indicate that even low levels of PBG can inhibit the enzyme responsible for breaking it down, thereby causing an immediate increase in ALA levels, contributing to the symptoms seen in acute porphyrias.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!